The effect of growth hormone replacement (GHR) on quality of life, physical and cardiovascular risk in conventionally replaced TBI (traumatic brain injury) induced growth hormone deficient (GHD) hypopituitary adults

Trial Profile

The effect of growth hormone replacement (GHR) on quality of life, physical and cardiovascular risk in conventionally replaced TBI (traumatic brain injury) induced growth hormone deficient (GHD) hypopituitary adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Somatropin (Primary)
  • Indications Somatotropin deficiency
  • Focus Pharmacodynamics
  • Sponsors Merck Serono; Roche
  • Most Recent Events

    • 14 Jul 2010 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 04 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top